

# Sarmad Sadeghi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8451741/publications.pdf>

Version: 2024-02-01

11  
papers

136  
citations

1684188

5  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Effectiveness of Screening Strategies for Lynch Syndrome. Journal of the National Cancer Institute, 2015, 107, .	6.3	44
2	Comparative effectiveness of screening strategies for colorectal cancer. Cancer, 2017, 123, 1516-1527.	4.1	41
3	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clinical Genitourinary Cancer, 2020, 18, 351-360.e3.	1.9	14
4	Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer, 2019, 17, 241-247.e1.	1.9	11
5	Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 428-434.	1.3	6
6	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clinical Advances in Hematology and Oncology, 2017, 15, 543-551.	0.3	6
7	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer, 2019, 125, 3853-3863.	4.1	4
8	Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have?. European Urology Focus, 2020, 6, 623-626.	3.1	4
9	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 459.e15-459.e24.	1.6	3
10	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clinical Advances in Hematology and Oncology, 2017, 15, 466-477.	0.3	3
11	EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. Pathology Research and Practice, 2020, 216, 152967.	2.3	0